In addition to the previously mentioned improvements in cardiometabolic factors, the rimonabant 20 mg group also showed a decrease in alanine aminotransferase (ALT), which is typically elevated in hepatic steatosis [163,209]. This evidence concerns the gene GPT and fatty liver disease.